

Marie Hudson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/822081/publications.pdf>

Version: 2024-02-01

186
papers

5,722
citations

66343

42
h-index

106344

65
g-index

187
all docs

187
docs citations

187
times ranked

7402
citing authors

#	ARTICLE	IF	CITATIONS
1	Measuring the Impact of <scp>MyLupusGuide</scp> in Canada: Results of a Randomized Controlled Study. <i>Arthritis Care and Research</i> , 2023, 75, 529-539.	3.4	4
2	Barriers and Facilitators to Physical Activity for People With Scleroderma: A Scleroderma Patientâ€Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2022, 74, 1300-1310.	3.4	4
3	Autoantibody profiles delineate distinct subsets of scleromyositis. <i>Rheumatology</i> , 2022, 61, 1148-1157.	1.9	16
4	NT-proBNP, hs-cTnT, and CRP predict the risk of cardiopulmonary outcomes in systemic sclerosis: Findings from the Canadian Scleroderma Research Group. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 62-70.	1.7	6
5	Association between autoantibodies in systemic sclerosis and cancer in a national registry. <i>Rheumatology</i> , 2022, 61, 2905-2914.	1.9	11
6	Challenges of Perceived <scp>Selfâ€Management</scp> in Lupus. <i>Arthritis Care and Research</i> , 2022, 74, 1113-1121.	3.4	8
7	The Effect of <scp>Antiâ€Scl</scp>â€70 Antibody Determination Method on Its Predictive Significance for Interstitial Lung Disease Progression in Systemic Sclerosis. <i>ACR Open Rheumatology</i> , 2022, 4, 345-351.	2.1	12
8	Influenza Vaccine Hesitancy and Its Determinants Among Rheumatology Patients. <i>ACR Open Rheumatology</i> , 2022, 4, 352-362.	2.1	4
9	Geographical distribution of systemic sclerosis in Canada: An ecologic study based on the Canadian Scleroderma Research Group. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 1095-1097.	1.2	2
10	Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program. <i>Pilot and Feasibility Studies</i> , 2022, 8, 45.	1.2	3
11	Myositis with prominent B-cell aggregates causing shrinking lung syndrome in systemic lupus erythematosus: a case report. <i>BMC Rheumatology</i> , 2022, 6, 11.	1.6	1
12	Screening and management of subclinical interstitial lung disease in systemic sclerosis: an international survey. <i>Rheumatology</i> , 2022, 61, 3401-3407.	1.9	3
13	Defining anti-synthetase syndrome: a systematic literature review.. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 309-319.	0.8	1
14	<i>Helicobacter pylori</i> serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors. <i>Oncolmmunology</i> , 2022, 11, .	4.6	11
15	Identifying barriers and facilitators to physical activity for people with scleroderma: a nominal group technique study. <i>Disability and Rehabilitation</i> , 2021, 43, 3339-3346.	1.8	12
16	A novel statistical method for modeling covariate effects in bisulfite sequencing derived measures of DNA methylation. <i>Biometrics</i> , 2021, 77, 424-438.	1.4	3
17	Mortality and morbidity in scleroderma renal crisis: A systematic literature review. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 21-36.	1.7	13
18	Designing Discrete Choice Experiments Using a Patient-Oriented Approach. <i>Patient</i> , 2021, 14, 389-397.	2.7	11

#	ARTICLE	IF	CITATIONS
19	Patient-provider communication about medication cost in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021, 40, 93-100.	2.2	6
20	Tofacitinib Persistence in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study. <i>Journal of Rheumatology</i> , 2021, 48, 16-24.	2.0	9
21	Statins and lower mortality in rheumatic diseases: An effect of immortal time bias?. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 211-218.	3.4	10
22	Association of Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis With Marked Improvement in Health-Related Quality of Life. <i>Arthritis and Rheumatology</i> , 2021, 73, 305-314.	5.6	10
23	Determinants and functional impacts of diaphragmatic involvement in patients with inclusion body myositis. <i>Muscle and Nerve</i> , 2021, 63, 497-505.	2.2	4
24	Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2197-2207.	4.2	31
25	Trigeminal neuralgia in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 318-323.	3.4	0
26	Scleroderma renal crisis. <i>Presse Medicale</i> , 2021, 50, 104063.	1.9	15
27	Allopurinol and cardiovascular events: Time-related biases in observational studies. <i>Arthritis Care and Research</i> , 2021, , .	3.4	3
28	Capillary basement membrane reduplication in myositis patients with mild clinical features of systemic sclerosis supports the concept of "scleromyositis". <i>Acta Neuropathologica</i> , 2021, 142, 395-397.	7.7	7
29	Barriers and facilitators to influenza and pneumococcal vaccine hesitancy in rheumatoid arthritis: a qualitative study. <i>Rheumatology</i> , 2021, 60, 5257-5270.	1.9	8
30	Association Between Immunosuppressive Therapy and Incident Risk of Interstitial Lung Disease in Systemic Sclerosis. <i>Chest</i> , 2021, 160, 2158-2162.	0.8	5
31	Reply. <i>Arthritis and Rheumatology</i> , 2021, 73, 2349-2349.	5.6	0
32	Histopathological features of systemic sclerosis-associated myopathy: A scoping review. <i>Autoimmunity Reviews</i> , 2021, 20, 102851.	5.8	17
33	Effectiveness of Allopurinol in Reducing Mortality: Time-Related Biases in Observational Studies. <i>Arthritis and Rheumatology</i> , 2021, 73, 1749-1757.	5.6	13
34	Risk of rheumatic disease in breast implant users: a qualitative systematic review. <i>Gland Surgery</i> , 2021, 10, 2557-2576.	1.1	3
35	Thousands of CpGs Show DNA Methylation Differences in ACPA-Positive Individuals. <i>Genes</i> , 2021, 12, 1349.	2.4	2
36	Association between gastroprotective agents and risk of incident interstitial lung disease in systemic sclerosis. <i>Respiratory Medicine</i> , 2021, 185, 106482.	2.9	1

#	ARTICLE	IF	CITATIONS
37	A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101707.	3.3	22
38	Distribution and trajectory of direct and indirect costs of idiopathic inflammatory myopathies. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 983-988.	3.4	6
39	The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial. <i>Trials</i> , 2021, 22, 856.	1.6	4
40	Immunosuppression does not prevent severe gastrointestinal tract involvement in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 131, 142-148.	0.8	0
41	Immunosuppression does not prevent severe gastrointestinal tract involvement in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 142-148.	0.8	6
42	Impact of using concomitant conventional DMARDs on adherence to biologic DMARD treatment in rheumatoid arthritis: Multi-centre, population-based cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, , .	3.4	0
43	Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis. <i>Rheumatology</i> , 2020, 59, 1108-1117.	1.9	12
44	Health-related quality of life in systemic sclerosis before and after autologous haematopoietic stem cell transplant—a systematic review. <i>Rheumatology</i> , 2020, 59, 779-789.	1.9	16
45	The Accuracy of the Patient Health Questionnaire-9 Algorithm for Screening to Detect Major Depression: An Individual Participant Data Meta-Analysis. <i>Psychotherapy and Psychosomatics</i> , 2020, 89, 25-37.	8.8	67
46	Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist. <i>Journal of Rheumatology</i> , 2020, 47, 166-175.	2.0	47
47	Equivalency of the diagnostic accuracy of the PHQ-8 and PHQ-9: a systematic review and individual participant data meta-analysis. <i>Psychological Medicine</i> , 2020, 50, 1368-1380.	4.5	175
48	Comparative safety of biologic versus conventional synthetic DMARDs in rheumatoid arthritis with COPD: a real-world population study. <i>Rheumatology</i> , 2020, 59, 820-827.	1.9	5
49	Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients. <i>Arthritis Research and Therapy</i> , 2020, 22, 5.	3.5	48
50	Mammalian target of rapamycin is activated in the kidneys of patients with scleroderma renal crisis. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 152-158.	1.7	2
51	Long-term exposure to a mixture of industrial SO ₂ , NO ₂ , and PM _{2.5} and anti-citrullinated protein antibody positivity. <i>Environmental Health</i> , 2020, 19, 86.	4.0	23
52	Sunlight exposure, sun-protective behaviour, and anti-citrullinated protein antibody positivity: A general population-based study in Quebec, Canada. <i>Arthritis Care and Research</i> , 2020, , .	3.4	2
53	Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies. <i>RMD Open</i> , 2020, 6, e001357.	3.8	23
54	Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets. <i>Autoimmunity Reviews</i> , 2020, 19, 102583.	5.8	25

#	ARTICLE	IF	CITATIONS
55	Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort. <i>Autoimmunity Reviews</i> , 2020, 19, 102595.	5.8	44
56	Immunosuppressive treatment in diffuse cutaneous systemic sclerosis is associated with an improved composite response index (CRISS). <i>Arthritis Research and Therapy</i> , 2020, 22, 132.	3.5	5
57	Moving towards personalized treatments of immune-related adverse events. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 504-515.	27.6	189
58	Investigating associations between anti-nuclear antibody positivity and combined long-term exposures to NO ₂ , O ₃ , and PM _{2.5} using a Bayesian kernel machine regression approach. <i>Environment International</i> , 2020, 136, 105472.	10.0	20
59	Preferences for treatments to prevent rheumatoid arthritis in Canada and the influence of shared decision-making. <i>Clinical Rheumatology</i> , 2020, 39, 2931-2941.	2.2	15
60	Suboptimal Immunization Coverage among Canadian Rheumatology Patients in Routine Clinical Care. <i>Journal of Rheumatology</i> , 2020, 47, 770-778.	2.0	30
61	FRIO258â€¦CUMULATIVE INCIDENCE, SURVIVAL AND PREDICTORS OF PULMONARY HYPERTENSION IN SYSTEMIC SCLEROSIS SUBSETS: PAH IS NOT INCREASED IN LIMITED VS DIFFUSE PATIENTS BY ADJUSTED COMPETING RISK ANALYSIS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 713-713.	0.9	33
62	The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial. <i>JMIR Research Protocols</i> , 2020, 9, e16799.	1.0	7
63	An interim report of the Scleroderma Clinical Trials Consortium working groups. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 17-27.	1.7	13
64	Rheumatoid arthritis-relevant DNA methylation changes identified in ACPA-positive asymptomatic individuals using methylome capture sequencing. <i>Clinical Epigenetics</i> , 2019, 11, 110.	4.1	14
65	Whole-genome bisulfite sequencing in systemic sclerosis provides novel targets to understand disease pathogenesis. <i>BMC Medical Genomics</i> , 2019, 12, 144.	1.5	22
66	Abatacept initiation in rheumatoid arthritis and the risk of serious infection: A population-based cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1053-1058.	3.4	13
67	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. <i>Rheumatology</i> , 2019, , .	1.9	0
68	Preventing rheumatoid arthritis: Preferences for and predicted uptake of preventive treatments among high risk individuals. <i>PLoS ONE</i> , 2019, 14, e0216075.	2.5	25
69	Comparative safety of abatacept in rheumatoid arthritis with COPD: A real-world population-based observational study. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 366-372.	3.4	12
70	A comparison between childhood and adult onset systemic lupus erythematosus adjusted for ethnicity from the 1000 Canadian Faces of Lupus Cohort. <i>Rheumatology</i> , 2019, 58, 1393-1399.	1.9	15
71	Letter in response to "Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors". <i>European Journal of Cancer</i> , 2019, 112, 47-48.	2.8	2
72	Scleroderma Patient-centered Intervention Networkâ€”Scleroderma Support group Leader Education (SPIN-SSLED) program: non-randomised feasibility trial. <i>BMJ Open</i> , 2019, 9, e029935.	1.9	9

#	ARTICLE	IF	CITATIONS
73	Protocol for a partially nested randomized controlled trial to evaluate the effectiveness of the Scleroderma Patient-centered Intervention Network Support Group Leader Education (SPIN-SSLED) Program. <i>Trials</i> , 2019, 20, 717.	1.6	8
74	Immune Checkpoint Inhibitor Associated Rheumatic Adverse Events: a Review of Their Presentations and Treatments. <i>Current Treatment Options in Rheumatology</i> , 2019, 5, 272-289.	1.4	2
75	Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2019, 46, 166-175.	2.0	12
76	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , 2019, 71, 964-971.	5.6	41
77	Adverse events associated with immune checkpoint inhibitor treatment for cancer. <i>Cmaj</i> , 2019, 191, E40-E46.	2.0	36
78	Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study. <i>Rheumatology</i> , 2019, 58, 683-691.	1.9	38
79	Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality. <i>Rheumatology</i> , 2019, 58, 636-644.	1.9	34
80	Shortening self-report mental health symptom measures through optimal test assembly methods: Development and validation of the Patient Health Questionnaire-Depression-4. <i>Depression and Anxiety</i> , 2019, 36, 82-92.	4.1	16
81	Bicaudal D2 is a novel autoantibody target in systemic sclerosis that shares a key epitope with CENP-A but has a distinct clinical phenotype. <i>Autoimmunity Reviews</i> , 2018, 17, 267-275.	5.8	19
82	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 563-570.	0.9	50
83	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. <i>Rheumatology</i> , 2018, 57, 370-381.	1.9	53
84	Probability of major depression diagnostic classification using semi-structured versus fully structured diagnostic interviews. <i>British Journal of Psychiatry</i> , 2018, 212, 377-385.	2.8	53
85	Exercise habits and factors associated with exercise in systemic sclerosis: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. <i>Disability and Rehabilitation</i> , 2018, 40, 1997-2003.	1.8	17
86	Understanding coping strategies among people living with scleroderma: a focus group study. <i>Disability and Rehabilitation</i> , 2018, 40, 3012-3021.	1.8	8
87	Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes. <i>Epidemiology</i> , 2018, 29, 904-912.	2.7	14
88	Perspectives of patients, first-degree relatives and rheumatologists on preventive treatments for rheumatoid arthritis: a qualitative analysis. <i>BMC Rheumatology</i> , 2018, 2, 18.	1.6	23
89	Dermoskeletalics to preserve mobility and function in inclusion body myositis. <i>Neurology</i> , 2018, 91, 760-760.	1.1	3
90	Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC vascular working group report. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 249-252.	1.7	33

#	ARTICLE	IF	CITATIONS
91	Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease. <i>European Respiratory Review</i> , 2018, 27, 170102.	7.1	53
92	Immune-Mediated Necrotizing Myopathy and Dietary Sources of Statins. <i>Annals of Internal Medicine</i> , 2018, 168, 893.	3.9	7
93	Interstitial lung disease is associated with an increased risk of lung cancer in systemic sclerosis: Longitudinal data from the Canadian Scleroderma Research Group. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 221-227.	1.7	8
94	Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network hand exercise program (SPIN-HAND): Study protocol. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 91-97.	1.7	7
95	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. <i>Rheumatology</i> , 2018, 57, 1623-1631.	1.9	53
96	Determinants of health-related quality of life in a multinational systemic sclerosis inception cohort. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 53-60.	0.8	6
97	The association of sociodemographic and disease variables with hand function: a Scleroderma Patient-centered Intervention Network cohort study. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 88-94.	0.8	3
98	Influence of Education on Disease Activity and Damage in Systemic Lupus Erythematosus: Data From the 1000 Canadian Faces of Lupus. <i>Arthritis Care and Research</i> , 2017, 69, 124-132.	3.4	16
99	Towards developing criteria for scleroderma renal crisis: A scoping review. <i>Autoimmunity Reviews</i> , 2017, 16, 407-415.	5.8	32
100	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1207-1218.	0.9	107
101	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. <i>Rheumatology</i> , 2017, 56, 1302-1311.	1.9	51
102	Industrial air emissions, and proximity to major industrial emitters, are associated with anti-citrullinated protein antibodies. <i>Environmental Research</i> , 2017, 157, 60-63.	7.5	30
103	Transethnic meta-analysis identifies <i>GSDMA</i> and <i>PRDM1</i> as susceptibility genes to systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1150-1158.	0.9	77
104	Early Mortality in a Multinational Systemic Sclerosis Inception Cohort. <i>Arthritis and Rheumatology</i> , 2017, 69, 1067-1077.	5.6	139
105	The association of sociodemographic and objectively-assessed disease variables with fatigue in systemic sclerosis: an analysis of 785 Canadian Scleroderma Research Group Registry patients. <i>Clinical Rheumatology</i> , 2017, 36, 373-379.	2.2	9
106	Assessment of English-French differential item functioning of the Satisfaction with Appearance Scale (SWAP) in systemic sclerosis. <i>Body Image</i> , 2017, 22, 97-102.	4.3	5
107	Rapidly progressive melanoma differentiation-associated protein 5-positive amyopathic dermatomyositis in an HIV-positive patient. <i>JAAD Case Reports</i> , 2017, 3, 158-161.	0.8	3
108	Cutaneous Lymphangiectasia in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 446-446.	5.6	1

#	ARTICLE	IF	CITATIONS
109	Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 488-508.	3.4	37
110	The Comparability of Functional Assessment of Chronic Illness Therapy - Fatigue Scores between Cancer and Systemic Sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 57-63.	1.7	2
111	Do patients and health care providers have discordant preferences about which aspects of treatments matter most? Evidence from a systematic review of discrete choice experiments. <i>BMJ Open</i> , 2017, 7, e014719.	1.9	71
112	Relationship between calcium channel blockers and skin fibrosis in patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 56-60.	0.8	2
113	Patient participation in patient-reported outcome instrument development in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 184-192.	0.8	7
114	Subsets in systemic sclerosis: one size does not fit all. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 298-306.	1.7	11
115	Exploring Sources of Emotional Distress among People Living with Scleroderma: A Focus Group Study. <i>PLoS ONE</i> , 2016, 11, e0152419.	2.5	22
116	Statins and Risk of Rheumatoid Arthritis: A Nested Caseâ€“Control Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 2603-2611.	5.6	30
117	Validation of the Selfâ€“Efficacy for Managing Chronic Disease Scale: A Scleroderma Patientâ€“Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2016, 68, 1195-1200.	3.4	31
118	Reply. <i>Arthritis Care and Research</i> , 2016, 68, 1053-1054.	3.4	1
119	Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues. <i>Rheumatology</i> , 2016, 56, kew441.	1.9	13
120	Comparative effectiveness research with administrative health data in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2016, 12, 358-366.	8.0	15
121	Calcinosis is associated with digital ischaemia in systemic sclerosisâ€“a longitudinal study. <i>Rheumatology</i> , 2016, 55, 2148-2155.	1.9	52
122	Improving care of autoimmune connective tissue diseases: Lessons from longitudinal cohorts. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 1-2.	3.3	1
123	Summed and Weighted Summary Scores for the Medsger Disease Severity Scale Compared with the Physicianâ€™s Global Assessment of Disease Severity in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2016, 43, 1510-1518.	2.0	12
124	No Evidence for Depression Screening in Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 992-992.	2.0	2
125	Relationship Between Disease Characteristics and Oral Radiologic Findings in Systemic Sclerosis: Results From a Canadian Oral Health Study. <i>Arthritis Care and Research</i> , 2016, 68, 673-680.	3.4	24
126	Development and Validation of the Body Concealment Scale for Scleroderma. <i>Arthritis Care and Research</i> , 2016, 68, 1158-1165.	3.4	11

#	ARTICLE	IF	CITATIONS
127	An evaluation of methods correcting for cell-type heterogeneity in DNA methylation studies. <i>Genome Biology</i> , 2016, 17, 84.	8.8	137
128	Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. <i>Arthritis Research and Therapy</i> , 2016, 18, 20.	3.5	18
129	funtooNorm: an R package for normalization of DNA methylation data when there are multiple cell or tissue types. <i>Bioinformatics</i> , 2016, 32, 593-595.	4.1	22
130	The Impact of Pain and Itch on Functioning and Health-Related Quality of Life in Systemic Sclerosis: An Exploratory Study. <i>Journal of Pain and Symptom Management</i> , 2016, 52, 43-53.	1.2	32
131	Fine particulate air pollution and systemic autoimmune rheumatic disease in two Canadian provinces. <i>Environmental Research</i> , 2016, 146, 85-91.	7.5	94
132	Anti-HMGBR antibodies in systemic sclerosis. <i>Medicine (United States)</i> , 2016, 95, e5280.	1.0	4
133	Health-Related Quality of Life (HRQoL) in Idiopathic Inflammatory Myopathy: A Systematic Review. <i>PLoS ONE</i> , 2016, 11, e0160753.	2.5	29
134	Reasons for non-participation in scleroderma support groups. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 56-62.	0.8	12
135	Novel Approaches to Discovery of Biomarkers in Rheumatoid Arthritis: Comment on the Article by Oswald et al. <i>Arthritis and Rheumatology</i> , 2015, 67, 2276-2277.	5.6	2
136	Scleroderma renal crisis. <i>Current Opinion in Rheumatology</i> , 2015, 27, 549-554.	4.3	8
137	An epigenome-wide association study of total serum immunoglobulin E concentration. <i>Nature</i> , 2015, 520, 670-674.	27.8	193
138	Fine particulate air pollution, nitrogen dioxide, and systemic autoimmune rheumatic disease in Calgary, Alberta. <i>Environmental Research</i> , 2015, 140, 474-478.	7.5	54
139	The Canadian Systemic Sclerosis Oral Health Study II: the relationship between oral and global health-related quality of life in systemic sclerosis. <i>Rheumatology</i> , 2015, 54, 692-696.	1.9	20
140	The Canadian Systemic Sclerosis Oral Health Study IV: oral radiographic manifestations in systemic sclerosis compared with the general population. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2015, 120, 104-111.	0.4	40
141	Can the Cancer-related Fatigue Case-definition Criteria Be Applied to Chronic Medical Illness? A Comparison between Breast Cancer and Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2015, 42, 1156-1162.	2.0	5
142	Antinuclear antibody-negative systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 680-686.	3.4	60
143	Treatment Algorithms in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2015, 67, 1237-1245.	3.4	88
144	Thinking outside the box—The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 184-189.	3.4	29

#	ARTICLE	IF	CITATIONS
145	Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects. <i>Autoimmunity</i> , 2015, 48, 542-551.	2.6	29
146	2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis Outperform the 1980 Criteria: Data From the Canadian Scleroderma Research Group. <i>Arthritis Care and Research</i> , 2015, 67, 582-587.	3.4	60
147	Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S131-5.	0.8	24
148	Protective role of interleukin-6 in systemic sclerosis gastrointestinal tract involvement: case report and review of the literature. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S179-81.	0.8	8
149	The Comparability of English, French and Dutch Scores on the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F): An Assessment of Differential Item Functioning in Patients with Systemic Sclerosis. <i>PLoS ONE</i> , 2014, 9, e91979.	2.5	13
150	Absence of an association between anti-Ro antibodies and prolonged QTc interval in systemic sclerosis: A multicenter study of 689 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 338-344.	3.4	28
151	The Canadian systemic sclerosis oral health study: orofacial manifestations and oral health-related quality of life in systemic sclerosis compared with the general population. <i>Rheumatology</i> , 2014, 53, 1386-1394.	1.9	65
152	Rheumatoid arthritis prevalence in Quebec. <i>BMC Research Notes</i> , 2014, 7, 937.	1.4	23
153	Diagnostic criteria of systemic sclerosis. <i>Journal of Autoimmunity</i> , 2014, 48-49, 38-41.	6.5	44
154	Systemic Sclerosis Sine Scleroderma: A Multicenter Study of 1417 Subjects. <i>Journal of Rheumatology</i> , 2014, 41, 2179-2185.	2.0	63
155	Autoantibodies to the Rpp25 Component of the Th/To Complex are the Most Common Antibodies in Patients with Systemic Sclerosis without Antibodies Detectable by Widely Available Commercial Tests. <i>Journal of Rheumatology</i> , 2014, 41, 1334-1343.	2.0	22
156	ImmunoChIP Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. <i>American Journal of Human Genetics</i> , 2014, 94, 47-61.	6.2	182
157	Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis—Results from the International Scleroderma Renal Crisis Survey. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 666-672.	3.4	115
158	An Assessment of the Measurement Equivalence of English and French Versions of the Center for Epidemiologic Studies Depression (CES-D) Scale in Systemic Sclerosis. <i>PLoS ONE</i> , 2014, 9, e102897.	2.5	9
159	The validity of administrative data to identify hip fractures is high—a systematic review. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 278-285.	5.0	71
160	Comparison of different measures of diffusing capacity for carbon monoxide (DLCO) in systemic sclerosis. <i>Clinical Rheumatology</i> , 2013, 32, 1467-1474.	2.2	7
161	The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context. <i>BMJ Open</i> , 2013, 3, e003563.	1.9	104
162	Clinical Correlates of CENP-A and CENP-B Antibodies in a Large Cohort of Patients with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2012, 39, 787-794.	2.0	54

#	ARTICLE	IF	CITATIONS
163	Longitudinal Study of Renal Function in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2012, 39, 1829-1834.	2.0	20
164	Immunosuppression for interstitial lung disease in systemic sclerosis – novel insights and opportunities for translational research. <i>Journal of Cell Communication and Signaling</i> , 2012, 6, 187-190.	3.4	4
165	Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. <i>Arthritis Care and Research</i> , 2012, 64, 519-524.	3.4	117
166	Corticosteroids and the risk of scleroderma renal crisis: a systematic review. <i>Rheumatology International</i> , 2012, 32, 645-653.	3.0	76
167	Modeling smoking in systemic sclerosis: A comparison of different statistical approaches. <i>Arthritis Care and Research</i> , 2011, 63, 570-578.	3.4	12
168	Cigarette smoking in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2011, 63, 230-238.	6.7	74
169	Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. <i>Rheumatology</i> , 2011, 50, 762-767.	1.9	188
170	Systemic Sclerosis. <i>Medicine (United States)</i> , 2010, 89, 159-165.	1.0	45
171	Avoiding common pitfalls in the analysis of observational studies of new treatments for rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2010, 62, 805-810.	3.4	30
172	Psychological health and well-being in systemic sclerosis: State of the science and consensus research agenda. <i>Arthritis Care and Research</i> , 2010, 62, 1181-1189.	3.4	79
173	Discordance between Patient and Physician Assessments of Disease Severity in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2010, 37, 2307-2312.	2.0	32
174	An International, Web-Based, Prospective Cohort Study to Determine Whether the Use of ACE Inhibitors prior to the Onset of Scleroderma Renal Crisis Is Associated with Worse Outcomes – Methodology and Preliminary Results. <i>International Journal of Rheumatology</i> , 2010, 2010, 1-7.	1.6	9
175	Validity of Self-Reported Comorbidities in Systemic Sclerosis: Table 1.. <i>Journal of Rheumatology</i> , 2009, 36, 1477-1480.	2.0	3
176	Clinical Correlates of Self-reported Physical Health Status in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2009, 36, 1226-1229.	2.0	16
177	Quality of Life in Patients with Systemic Sclerosis Compared to the General Population and Patients with Other Chronic Conditions. <i>Journal of Rheumatology</i> , 2009, 36, 768-772.	2.0	64
178	Work Disability in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2009, 36, 2481-2486.	2.0	61
179	Time to diagnosis in systemic sclerosis: Is sex a factor?. <i>Arthritis and Rheumatism</i> , 2009, 61, 274-278.	6.7	35
180	Health-related quality of life in systemic sclerosis: A systematic review. <i>Arthritis and Rheumatism</i> , 2009, 61, 1112-1120.	6.7	129

#	ARTICLE	IF	CITATIONS
181	Quality of life in systemic sclerosis: Psychometric properties of the World Health Organization Disability Assessment Schedule II. <i>Arthritis and Rheumatism</i> , 2008, 59, 270-278.	6.7	68
182	Clinical correlates of quality of life in systemic sclerosis measured with the World Health Organization Disability Assessment Schedule II. <i>Arthritis and Rheumatism</i> , 2008, 59, 279-284.	6.7	47
183	Polyautoimmunity and familial autoimmunity in systemic sclerosis. <i>Journal of Autoimmunity</i> , 2008, 31, 156-159.	6.5	101
184	Update on Indices of Disease Activity in Systemic Sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2007, 37, 93-98.	3.4	57
185	Hypocomplementemia in systemic sclerosis—clinical and serological correlations. <i>Journal of Rheumatology</i> , 2007, 34, 2218-23.	2.0	21
186	The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies. <i>Journal of Rheumatology</i> , 2003, 30, 2385-91.	2.0	35